| Autor: |
Araújo-Silva, Gabriel, de Macêdo, Luã B., Mouta, Andressa N., de Oliveira, Maria Gláucia C., Arcoverde, Kathryn N., Solon, Lilian G. S., Perez-Urizar, José T., de Paula, Valéria V. |
| Předmět: |
|
| Zdroj: |
Animals (2076-2615); Mar2024, Vol. 14 Issue 6, p929, 12p |
| Abstrakt: |
Simple Summary: The combination of an opioid compound with a nonsteroidal anti-inflammatory drug can lead to additive or enhanced effects while minimizing adverse reactions. Recently, we reported the pharmacokinetic profiles of metamizole and tramadol in donkeys at single doses and without association. However, no studies have reported on the pharmacokinetic profile of the combination of tramadol and metamizole. The objective of this research was to assess pharmacokinetic profile of metamizole co-administered with tramadol at single dose. Behavioral changes in the animals were observed, and at specific intervals, blood samples were taken for subsequent analysis. Analyses were performed using ultra-high-performance liquid chromatography-tandem mass spectrometry. The findings indicate that tramadol and its metabolite presented modified profiles, implying that metamizole and tramadol interact and affect each other's metabolic processes at the dosages used in this study. Clinical researches are necessary to determine the optimal that effectively addresses the pain relief requirements of the species. Our objective was to assess the pharmacokinetic characteristics of metamizole when administered together with tramadol in a single intravenous dose to donkeys. Ten male animals received 10 mg∙kg−1 of dipyrone associated with 2 mg∙kg−1 of tramadol (T2M10) and 25 mg∙kg−1 of dipyrone with 2 mg∙kg−1 of tramadol (T2M25). Venous blood samples were taken from groups to determine the pharmacokinetics after drug administration, using initial brief intervals that were followed by extended periods until 48 h. Restlessness and ataxia were observed in two animals in the T2M25 group. Analysis revealed prolonged detectability of tramadol, 4-methylamine antipyrine, 4-aminoantipyrine (up to 24 h), and O-desmethyltramadol (up to 12 h) after administration. Although metamizole and its metabolites showed no significant pharmacokinetic changes, tramadol and O-desmethyltramadol exhibited altered profiles, likely because of competition for the active sites of CYP450 enzymes. Importantly, the co-administration of metamizole increased the bioavailability of tramadol and O-desmethyltramadol in a dose-dependent manner, highlighting their potential interactions and emphasizing the need for further dose optimization in donkey analgesic therapies. In conclusion, metamizole co-administered with tramadol interferes with metabolism and this interference can change the frequency of drug administration and its analgesic efficacy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
